Navigation Links
Epstein-Barr virus protein crucial to its role in blood cancers

Researchers at the University of Pennsylvania School of Medicine have identified a link between a critical cancer pathway and an Epstein-Barr Virus (EBV) protein known to be expressed in a number of EBV-associated cancers. Their findings demonstrate a new mechanism by which EBV transforms human B cells from the immune system into cancerous cells, which can lead to development of B-cell lymphomas.

Erle S. Robertson, PhD, Associate Professor of Microbiology and Director of Tumor Virology, with Penn's Abramson Cancer Center and MD/PhD student Jason Knight, published their results in the early March issue of Molecular and Cellular Biology.

Using human cell cultures infected with the Epstein-Barr virus, the investigators found that a specific viral protein targets a molecule that normally regulates the cell-cycle progression, or duplication process, of resting B cells. In the presence of this viral protein ?called EBNA3C (for EBV nuclear antigen) ?the cell cycle of the usually quiescent human B cells gets a jump start, which ultimately initiates uncontrolled growth.

EBV, a member of the herpesvirus family and one of the most common human viruses, plays a role in cancers such as lymphoproliferative diseases in transplant or AIDS patients, Burkitt's lymphoma, Hodgkin's lymphoma, and nasopharyngeal carcinoma, and also causes the well-known disease, infectious mononucleosis. As many as 95 percent of adults 20 years and older have been infected with EBV, but show no symptoms.

"Viruses that are associated with cancers typically target the cell cycle to gain control," says Robertson. "However, this is the first time that laboratory research into how EBV drives the cancer process has directly identified a critical component of the cell cycle for control. Now we can develop targeted therapeutics to disrupt the function of this viral protein." The researchers surmise that the first use of future therapies from these studies will be in lymphoprolifera tive disease in transplant and immunocompromised patients because this is a clear case of EBV-driven B-cell lymphoma.

The use of peptides to block the interaction between this essential EBV protein and the specific pathway in human B cells is currently underway. Initial studies show that the growth of EBV-associated cancer cells can be inhibited in tissue-culture assays. The investigators are actively pursuing this line of investigation for developing potential therapies.


'"/>

Source:University of Pennsylvania Medical Center


Related biology news :

1. U of T researchers map role of Epstein-Barr virus in cancer
2. Mechanism for Epstein-Barr virus proteins role in blood cancers discovered
3. Epstein-Barr virus may be associated with multiple sclerosis
4. Epstein-Barr virus might kick-start multiple sclerosis
5. Clue found to Epstein-Barr virus ability to form and sustain tumors
6. Association of herpesvirus with lung disorder questioned
7. Topical treatment shown to inhibit HIV and herpes simplex virus infection
8. Elusive HIV shape change revealed; Key clue to how virus infects cells
9. Newly discovered virus linked to childhood lung disorders and Kawasaki disease
10. Live Recombinant Adenovirus Vaccine Technique Explored
11. Marburg virus disease in Angola - update
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/9/2019)... ... March 07, 2019 , ... Murrieta Genomics , ... full day workshop presented by University of California Riverside’s EPIC SBDC focused on ... a.m. to 6 p.m. on Tuesday, March 17, 2019. The location is the Highlander ...
(Date:3/9/2019)... ... 2019 , ... On International Women’s Day, the Society for ... women in the field. The Women in Cancer Immunotherapy Network Leadership Institute ... emerging female leaders in the cancer immunotherapy field. , Scheduled for Aug. 19–20, ...
(Date:3/5/2019)... ... ... Join this live webinar on Thursday, March 21, 2019 at 1pm ... on data analysis without worrying about data management-related activities. , Clinical data lakes ... of data include:, , Clinical Trial Management Systems (CTMS) , ...
Breaking Biology News(10 mins):
(Date:3/15/2019)... ... March 15, 2019 , ... ... American Process Inc. and affiliate companies including AVAPCO LLC and API Intellectual ... the Thomaston Biorefinery and R&D center in Thomaston, Georgia, operations, research, and ...
(Date:3/14/2019)... PRINCETON, N.J. (PRWEB) , ... March 14, 2019 , ... ... will create challenges for companies to keep up. Traditional Regulatory intelligence ... times and adapting technology to get global Regulatory teams right Insights faster and cheaper. ...
(Date:3/14/2019)... ... March 14, 2019 , ... ... announcing that its Canadian partner, the Eye Machine Canada Inc., had been given ... pioneering technology for treating Age-Related Macular Degeneration (AMD). , The previous month, the ...
(Date:3/14/2019)... ... 2019 , ... The International Society for Pharmaceutical Engineering ... in Brussels, Belgium on 25–26 September 2019. This event is a leading interactive ... , “Biopharmaceuticals have become a main pillar in the pharmaceutical industry, with ...
Breaking Biology Technology: